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Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a
potentially curative therapy for patients with acute lym-
phoblastic leukemia (ALL). Risk stratification of ALL
varies across studies and generally includes a spectrum of
demographic (e.g., age), clinical (e.g., white blood cell
count, minimal residual disease, steroid sensitivity), phe-
notypic (B- versus T-cell origin), and cytogenetic character-
istics. Several cytogenetic risk stratification schemes have
been developed and are used as prognostic tools at diag-
nosis of ALL to guide treatment decisions. However, most
prior studies focusing on the prognostic significance of
cytogenetics in ALL were influenced by inclusion of
patients with Philadelphia chromosome-positive (Ph+) B-
ALL and defined for patients who received conventional
chemotherapies. 
Pivotal Medical Research Council–Eastern Cooperative
Oncology Group (MRC-ECOG) and Southwest Oncology
Group (SWOG) clinical trials identified commonly recog-
nized Ph-negative (Ph–) cytogenetic risks, including
KMT2A (MLL) translocations at 11q23 associated with
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Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosisin acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalitieson outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with
Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-
myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for
International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional
metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in
patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients
with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical
Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of
leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse
[hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95%
CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14)
predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41).
This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex
karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and
all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival
(P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in
ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose sig-
nificant risks and yield inferior outcomes.
ABSTRACT
t(4;11)(q21;q23), complex karyotype, t(8;14)(q24;q32), low
hypodiploidy, or near triploidy, among others.1 However,
only a subset of Ph– patients underwent allogeneic HCT in
those trials. Thus, the applicability of existing cytogenetic
risk classifications for allogeneic transplant recipients with
ALL remains uncertain due to the relatively low frequency
of specific Ph– cytogenetic abnormalities and the modest
size of prior studies. In a single-center retrospective cohort
study of 333 allograft recipients with ALL, cytogenetic risk
did not predict survival after allogeneic HCT.2 Notably, in
that study Ph+ patients accounted for the majority of
patients in the poor-risk cytogenetic group, and the cyto-
genetic risk scheme used was chosen arbitrarily. Another
study on allogeneic HCT in Ph– ALL (n=373), conducted in
Japan, found no difference in overall survival between
patients with high-risk [t(4;11), t(8;14), low hypodiploidy,
and complex karyotype] and standard-risk cytogenetics.3
A more recent analysis of Ph– B-ALL patients from
GRAALL clinical trials identified t(4;11)/KMT2A-AFF1 and
t(v;14q32)/IGH as markers of poor clinical outcome; how-
ever, only a third of the trial patients underwent allogeneic
HCT in first complete remission.4
In view of the conflicting prior data, we analyzed
Center for International Blood and Marrow Transplant
Research (CIBMTR) registry data to determine the prog-
nostic impact of individual conventional (G-banding)
cytogenetic abnormalities and major previously estab-
lished Ph– cytogenetic risk classifications (Table 1) on
outcomes of allogeneic HCT. We also developed an allo-
geneic HCT‐specific cytogenetic classification of Ph–
ALL for prediction of post-transplant relapse and sur-
vival. 
Methods
Data source
Study data were obtained from the CIBMTR registry
which is a voluntary network of over 450 blood and mar-
row transplant centers in the USA and around the world.
Participating centers contributed detailed transplant-relat-
ed information longitudinally to the centralized data
management and statistical centers at the Medical
College of Wisconsin (Milwaukee, WI, USA) and the
National Marrow Donor Program (NMDP) (Minneapolis,
MN, USA). Like all observational research conducted by
the CIBMTR, this study adhered to strict federal regula-
tions for the protection of human research subjects.
Protected health information used in this study was col-
lected and maintained in CIBMTR’s capacity as a Public
Health Authority under the Health Insurance Portability
Accountability (HIPAA) Privacy Rule.
Ph– ALL cytogenetics and allogeneic HCT outcomes 
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Table 1. Major established cytogenetic risk classifications of Philadelphia chromosome-negative acute lymphoblastic leukemia.
Study                                        Design highlights                                 Risk group             Cytogenetic abnormalities
MRC-ECOG (Moorman et al.     • Randomized phase III                             Poor                           t(4;11), t(8;14)*, complex* (≥5 abnormalities without
Blood 2007)                                     • 796 pts with abnormal                                                                 translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)*
                                                           cytogenetics                                               Other                        All other karyotypes
                                                           • 310 alloHCT
                                                                                                                                     Good                          High hyperdiploidy (>50), del(9p)
Modified MRC-ECOG                   • Randomized phase III                             Very high                   t(4;11), t(8;14), complex (≥5 abnormalities without 
(Pullarkat et al. Blood 2008)       • 140 pts with evaluable                                                                 translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)
                                                           cytogenetics                                              High                           Other 11q23/MLL, monosomy 7§, del(7p), +8§, t(1;19) or t(17;19),
                                                           • Re-classified by MRC-ECOG                                                     t(5;14)
                                                           • 19 alloHCT                                                  Intermediate           Normal diploid, low hyperdiploidy (47-50 chr), abnormal 11q (not
                                                                                                                                                                         MLL), del(6q), del(17p), del(9p), del(12p), del(13q), t14q32, 
                                                                                                                                                                         t(10;14), tetraploidy (>80 chr), or any karyotype abnormalities not 
                                                                                                                                                                         identified with a different risk group
                                                                                                                                     Standard                   High hyperdiploidy (>50 chr)
SWOG (Pullarkat et al.                 • Randomized phase III trial                     Unfavorable             Monosomy 7, +8, and 11q23/MLL gene rearrangements
Blood 2008)                                     • 140 pts with evaluable                             Miscellaneous         Any other abnormal karyotype
                                                           cytogenetics                                              Normal                      Normal karyotype
                                                           • 19 alloHCT
NILG-ALL (Bassan et al.              • Phase II                                                       Adverse                     t(4;11) and/or MLL-AF4, +8, near triploidy, low hypodiploidy, 
Blood 2009)                                     • 276 with evaluable cytogenetics                                                complex (≥3 abnormalities), del(6q), t(8;14)
                                                                                                                                     Non-adverse            t(1;19) and/or E2A-PBX1, hyperdiploid, other karyotype 
                                                                                                                                                                         abnormalities not identified with a different risk group
                                                                                                                                    Normal                      Normal karyotype
North UK (Moorman et al.          • Observational                                            Poor                           t(4;11), t(8;14), t(14;18), complex (≥5 abnormalities without
Blood 2010)                                     • 292 pts with evaluable cytogenetics                                         translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)
                                                                                                                                     Standard                   All other karyotypes
GIMEMA 0496 (Mancini et al.    • Phase II                                                       High                           t(4;11), t(1;19)
Blood 2005)                                   • 282 pts with evaluable cytogenetics     Intermediate           del(6q) and other karyotypes
                                                                                                                                    Standard                   normal karyotype, del(9p)
MRC-ECOG: Medical Research Council-Eastern Cooperative Oncology Group; SWOG: Southwest Oncology Group; NILG: Northern Italy Leukemia Group; GIMEMA: Gruppo Italiano Malattie
EMatologiche dell'Adulto; alloHCT: allogeneic hematopoietic cell transplantation; pts: patients; chr: chromosomes; MLL: mixed lineage leukemia *Independent predictors. §Unfavorable
by Cancer and Leukemia Group B classification.
Selection of patients
The initial study population included 3,275 adults (age ≥16
years) with Ph– ALL in first or second complete remission (CR1 or
CR2, corresponding to morphological remission with <5% bone
marrow blasts) who underwent allogeneic HCT between 1995-
2011 and whose data were reported to the CIBMTR. Further
restriction of the study population to the recipients of HLA-
matched sibling and unrelated donor  peripheral blood or bone
marrow allografts (with consent to submit at least 100 days of
post-transplant research reports) resulted in 2,903 eligible study
participants. The CIBMTR data center requested original cytoge-
netic reports for cases with reportedly abnormal or unknown
cytogenetics at either the time of diagnosis or prior to allogeneic
HCT. Cytogenetic reports were received from participating cen-
ters for 1,013 cases, all of which were reviewed and validated by
the study’s principal investigators (AL, MD). Data on cytogenetics
from the existing CIBMTR records were used for 743 cases for
which no original cytogenetic reports were received from the
queried centers. For 342 cases (12%) with prior CIBMTR cytoge-
netics status reported as “unknown” or “not tested” the original
cytogenetic reports were requested, but not received from the
transplant centers. Normal conventional cytogenetic results were
confirmed with over 95% accuracy upon review of all original
reports received and the remaining 805 cases with normal cytoge-
netics were included in the final study sample of 1,099 patients
with normal cytogenetics reported. Patients with abnormal con-
ventional cytogenetics (n=632) were included in the study popula-
tion after review of all available original cytogenetic reports. Thus,
a total study population of 1,731 patients from 256 reporting cen-
ters and 38 countries was analyzed.
Cytogenetics
Blood and marrow samples at the time of ALL diagnosis and
prior to transplantation were cultured and evaluated for cytoge-
netic abnormalities by G-banding according to the standard prac-
tices of the participating centers. Original cytogenetic data report-
ed to the CIBMTR conformed to the International System of
Cytogenetic Nomenclature (ISCN).5 According to the ISCN, a
clonal abnormality was defined as the presence of a gain of the
same chromosome or the presence of the same structural abnor-
mality in ≥2 cells or the loss of the same chromosome in ≥3 cells.
A normal conventional cytogenetic result was defined as the
absence of clonal abnormalities in at least 20 metaphase cells.
Abnormal cytogenetics were classified according to previously
established cytogenetic risk classifications for Ph– ALL (Table 1).
Standard definitions for hypodiploid, hyperdiploid, complex, and
monosomal karyotypes were based on the following modal chro-
mosome numbers: (i) low hypodiploidy (30-39 chromosomes), (ii)
high hypodiploidy (40-43), (iii) low hyperdiploidy (47-50), (iv)
high hyperdiploidy (>50), (v) near triploidy (60-78), (vi) tetraploidy
(>80), (vii) complex with ≥5 abnormalities6-8 (adopted here) in the
absence of established translocations or ploidy abnormalities; or
≥3 abnormalities used exclusively by the Northern Italy Leukemia
Group (NILG)9 (Table 1), and (viii) monosomal (≥2 autosomal
monosomies or a single autosomal monosomy combined with a
single structural abnormality). Fluorescence in situ hybridization
(FISH) findings and/or other molecular data were available for the
minority of patients and were, therefore, only used to validate
cytogenetic reports when available.
Statistical analysis
Individual Ph– cytogenetic abnormalities were included in the
analysis if they were detected in ≥20 patients or in <20 patients
but with previously established prognostic significance in ALL.
Cytogenetic abnormalities included high hyperdiploidy (n=29),
tetraploidy (n=9), near triploidy (n=6), low hypodiploidy (n=11),
complex karyotype (n=51), monosomal karyotype (n=84), mono-
somy 17 (n=21), i(17q) (n=5), del(17p) (n=6), t(1;19) (n=33), t(4;11)
(n=95), t(8;14) (n=10), t(10;11) (n=8), t(11;19) (n=10), add(5q) (n=7),
del(5q) (n=20), add(7p) (n=8), i(7q) (n=10), add(12p) (n=10),
del(12p) (n=18), t(14;18) (n=6), del(6q) (n=48), del(7q) (n=7), mono-
somy 7 (n=33), add(9p) (n=11), del(9p) (n=52), i(9q) (n=17),
add(12p) (n=10), del(12p) (n=18), del(11q) (n=18), del(13q) (n=12),
and trisomy 8 (n=35). Each cytogenetic abnormality was tested
individually for its association with post-HCT relapse while
adjusted for potential confounders. Statistically significant
(P<0.05) clinical factors other than cytogenetics [conditioning reg-
imen, remission status, donor type, and graft-versus-host disease
(GvHD) prophylaxis among other potential confounders] were
retained in the multivariable Cox proportional hazards model.
Abnormalities with a hazard ratio (HR) ≥1.4 for relapse were sub-
sequently grouped as adverse risk; abnormalities with a HR ≤0.6
for relapse were grouped as favorable, whereas all other abnor-
malities, and normal cytogenetics, were grouped as intermediate
risk. Relapse was used as the primary endpoint for evaluation of
individual cytogenetic abnormalities and it was calculated as the
cumulative incidence of ALL recurrence with treatment-related
mortality as the competing risk. Leukemia-free survival was used
as the primary endpoint for evaluation of previously established
and study-derived cytogenetic risk classifications and was defined
as the time to death or relapse with survivors in continuing com-
plete remission censored at last follow-up. Adjusted probabilities
of leukemia-free survival and relapse were calculated using multi-
variable models, stratified by cytogenetic risk scheme and weight-
ed by the pooled sample proportion value for each prognostic fac-
tor.10,11 Overall survival was a secondary study endpoint and was
defined as the time to death from any cause with surviving
patients censored at last follow-up. Treatment failure (1 –
leukemia-free survival) and overall mortality (1 – overall survival)
were used to model all Cox regression HR estimates. SAS version
9.4 (SAS Institute, Cary, NC, USA) and GraphPad Prism version
7.04 were used for all data analysis and graphics. 
Results
Study population and transplant characteristics
A description of the entire study population and the dis-
tribution of the main study variables among patients with
abnormal and normal cytogenetics are summarized in
Table 2. The study cohort consisted predominantly of
young (82% <45 years) male (63%) patients with B-pre-
cursor ALL (69%). Patients with hyperleukocytosis (white
blood cell count >30×109/L for B-ALL and >100×109/L for
T-ALL) at the time of initial diagnosis accounted for 22%
of the entire cohort and 57% of patients underwent allo-
geneic HCT in CR1 with a median time to achieve CR1 of
6 weeks (range, 1-123). 
Post-transplant outcomes classified by established
cytogenetic schemes
Patients with abnormal cytogenetics had 5-year
leukemia-free and overall survival rates of 40% and 42%,
respectively, which were similar to those of patients with
a normal karyotype (both P>0.6). The cytogenetic risk cat-
egories defined by the MRC-ECOG, SWOG, NILG-ALL,
North UK, and GIMEMA 0496 (Table 1) had no prognostic
significance for leukemia-free survival, relapse, or overall
survival (all P-values >0.15). However, the cytogenetic risk
A. Lazaryan et al.
1332 haematologica | 2020; 105(5)
classification defined by the modified MRC-ECOG was
significantly associated with both treatment failure (over-
all P=0.02) and overall survival (overall P=0.03) in multi-
variable analyses adjusted for recipient age, disease status,
conditioning intensity, Karnofsky Performance Status,
donor type, and GvHD prophylaxis (Figures 1A and 2).
Significant associations between the modified MRC-
ECOG classification and major clinical outcomes
appeared to be largely driven by the favorable outcomes
of patients with standard-risk cytogenetics (n=24), all with
a high hyperdiploid karyotype. There was no difference
between high or very high modified MRC-ECOG cytoge-
netic risk groups compared to the intermediate group. In
contrast, good-risk cytogenetics according to the MRC-
ECOG classification included del(9p), in addition to high
hyperdiploidy, and was not significantly associated with
any of the clinical outcomes of interest. 
Individual cytogenetic abnormalities: relapse
Monosomy 7 [HR=2.11; 95% confidence interval (CI):
1.04-4.27, P=0.04] and complex karyotype (HR=1.69; 95%
CI: 1.06-2.69, P=0.03) were both associated with
increased risk of relapse in multivariable analysis adjusted
for conditioning intensity, ALL remission status prior to
transplantation, and monosomal karyotype (Figure 3,
Table 3). Patients with high hyperdiploidy had an estimat-
ed 54% lower risk of relapse, whereas those with del(7q),
t(8;14), t(11;19), del(11q), or a tetraploid/near triploid kary-
otype had a HR of at least 40% higher for relapse, which
did not reach statistical significance (Figure 3). The magni-
tude and strength of associations with relapse for the
remaining individual cytogenetic categories, such as tri-
somy 8, monosomal karyotype, monosomy 17,
del(17p)/i(17p), low hypodiploidy, del(6q), t(1;19), t(4;11),
and normal karyotype, did not demonstrate any meaning-
ful clinical associations (all HR between 0.6 and 1.4), and
none was statistically significant (all P-values >0.1). 
A significant interaction was detected between t(4;11)
and pre-transplant remission status (P<0.001) with the
adverse impact of t(4;11) on relapse observed only in
patients undergoing allogeneic HCT in CR2 (HR=2.82;
95% CI: 1.25-6.36, P=0.01), but not in CR1 (HR=0.86,95%
CI: 0.53-1.41, P=0.55).  
Individual cytogenetic abnormalities: treatment failure
Monosomy 7 (HR=1.97; 95% CI: 1.20-3.24, P=0.007)
and t(8;14) (HR=2.85; 95% CI: 1.35-6.02, P=0.006) were
Table 2. Patient and transplant characteristics.
Variables                                                     All          Cytogenetics    Cytogenetics
                                                                                     Abnormal            Normal
Number of patients                                            1731              632 (36.5)           1099 (63.5)
Number of centers                                              256                     178                         226
Recipient age, median (range), years      29 (16-68)        28 (16-65)            29 (16-68)
Gender, female, n (%)                                   636 (37)            234 (37)               402 (37)
Recipient race, n (%)
Caucasian                                                       1429 (83)           534 (84)               895 (81)
African-American                                            42 (2)                12 (2)                   30 (3)
Asian                                                                 154 (9)               49 (8)                 105 (10)
Other                                                                106 (7)               37 (6)                   69 (6)
Karnofsky score ≥ 90%, n (%)                    1245 (72)           459 (73)               786 (72)
Disease status prior to alloHCT, n (%)
CR1                                                                   990 (57)          395 (62.5)              595 (54)
CR2                                                                   741 (43)          237 (37.5)              504 (46)
Time to CR1, median (range), weeks       6 (1-123)          5 (2-123)              6 (1-113)
Time from CR1 to alloHCT1, median          3 (<1-16)         3 (<1-13)             4 (<1-16)
(range), months
Time from CR1 to relapse2,                       20 (<1-111)     18 (<1-103)          21 (1-111)
median (range), months
ALL lineage, n (%)
B-ALL                                                              1197 (69)           474 (75)               723 (66)
T-ALL                                                                393 (23)            121 (19)               272 (25)
Unknown                                                          141 (8)               37 (6)                  104 (9)
Hyperleukocytosis at diagnosis, n (%)
B-ALL (>30x109 WBC/L)                              299 (17)            150 (24)               149 (14)
T-ALL (>100x109 WBC/L)                               81 (5)                31 (5)                   50 (4)
Extramedullary ALL at diagnosis, n (%)
CNS                                                                   105 (6)               35 (6)                   70 (6)
Non-CNS                                                        202 (12)           70 (11)              132 (12)
Conditioning intensity, n (%)                               
MAC (+TBI)                                                  1343 (78)           522 (83)               821 (75)
MAC (-TBI)                                                     254 (15)             72 (11)                182 (17)
NMA/RIC                                                            98 (6)                28 (5)                   70 (7)
Unknown                                                          36 (2)               10 (2)                   26 (2)
GvHD prophylaxis, n (%)
Tacrolimus-based                                         576 (33)            217 (34)               359 (33)
Cyclosporine A-based                                 1000 (58)           350 (55)               650 (59)
T-cell depletion (ex-vivo)                           123 (7)               55 (9)                   68 (6)
In-vivo T-cell depletion, n (%)
Alemtuzumab                                                   46 (3)                19 (3)                   27 (2)
ATG                                                                   286 (17)             99 (16)                187 (17)
Graft source, n (%)
Bone marrow                                                 790 (46)            281 (44)               509 (46)
Peripheral blood                                           941 (54)            352 (46)               590 (54)
Donor type, n (%)
HLA-identical sibling                                    819 (47)            270 (43)               549 (50)
Well-matched unrelated donor                 469 (27)            188 (30)               281 (26)
Partially-matched/mismatched                 357 (21)            141 (22)               216 (20)
unrelated donor
Other related/unrelated donor                 172 (10)             70 (11)                 102 (9)
Donor/recipient CMV serostatus, n (%)
Donor+/recipient+                                      574 (33)            170 (27)               404 (37)
Donor+/recipient-                                        193 (11)             78 (12)                115 (10)
Donor-/recipient+                                        385 (22)            143 (23)               242 (22)
Donor-/recipient-                                          494 (29)            210 (33)               284 (26)
Unknown                                                           85 (5)                31 (5)                   54 (5)
Donor/recipient gender match, n (%)
Male-male                                                       691 (40)            256 (41)               435 (40)
Male-female                                                   340 (20)            127 (20)               213 (19)
Female-male                                                  401 (23)            142 (22)               259 (24)
Female-female                                              295 (17)            107 (17)               188 (17)
Unknown                                                          4 (<1)                    0                        4 (<1)
Year of alloHCT, n (%)                                           
1995-2000                                                         557 (32)            194 (31)               363 (33)
2001-2005                                                         604 (35)            217 (34)               387 (35)
2006-2011                                                         570 (33)            221 (35)               349 (32)
Median follow up of survivors 
(range), months                                            75 (2-224)        87 (3-224)            73 (2-218)
alloHCT: allogeneic hematopoietic cell transplantation; CR1: first complete remission; CR2:
second complete remission; ALL: acute lymphoblastic leukemia; WBC: white blood cell; CNS:
central nervous system; MAC: myeloablative conditioning; TBI: total body irradiation; NMA:
non-myeloablative; RIC: reduced-intensity conditioning; HLA: human leukocyte antigen;
GvHD: graft-versus-host disease; ATG: antithymocyte globulin; CMV: cytomegalovirus.1Referred
to patients in CR1. 2Referred to patients in CR2.
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continued in next column
prognostic for treatment failure after adjustments for
recipient age, pre-transplant remission status, condition-
ing intensity, donor type, and GvHD prophylaxis in mul-
tivariable analyses (Table 4). Trends toward increased risk
of treatment failure were observed for patients with
del(7q) (HR=2.16; 95% CI: 0.95-4.90, P=0.06) and
del(17p)/i(17q) (HR=1.95; 95% CI: 0.80-4.75, P=0.1). In
contrast, patients with high hyperdiploidy (HR=0.62; 95%
CI: 0.37-1.04, P=0.07) and monosomal karyotype
(HR=0.73; 95% CI: 0.54-1.01, P=0.05) trended toward less
risk of treatment failure. Although t(4;11) was not associ-
ated with treatment failure (HR=1.12; 95% CI: 0.85-1.48,
P=0.41) within the entire cohort or in CR1 patients (n=83)
(HR=0.98; 95% CI: 0.72-1.33, P=0.89),  it was associated
with a significantly higher risk of treatment failure in CR2
patients (n=11)  (HR=2.35; 95% CI: 1.25-4.43, P=0.008).
Individual cytogenetic abnormalities: overall mortality
After adjustment for recipient age (HR=1.55; 95% CI:
1.17-2.06, P<0.01 for age >55 years versus <40 years),
Karnofsky Performance Status <90 (HR=1.29; 95% CI:
1.12-1.48, P<0.001), ALL in CR2 (HR=1.56; 95% CI: 1.36-
1.77, P<0.001), myeloablative conditioning without total
body irradiation (HR=1.35; 95% CI: 1.13-1.62, P<0.001),
mismatched unrelated donor (HR=1.49; 95% CI: 1.27-
1.76, P<0.001), and GvHD prophylaxis (HR=1.41; 95% CI:
1.11-1.79, P=0.005 for non-calcineurin inhibitor- versus
tacrolimus-based) in multivariable analysis, only t(8;14)
was associated with higher mortality after allogeneic HCT
(HR=3.03; 95% CI: 1.44-6.41, P=0.004).
Novel allogeneic hematopoietic cell transplantation-
specific cytogenetic classification 
Based on the relapse model adjusted for significant clin-
ical factors and individual cytogenetic abnormalities
(Figure 3), the following cytogenetic markers with
HR≥1.4 were categorized as adverse risk (n=125): mono-
somy 7, complex karyotype, del(7q), t(8;14), t(11;19),
del(11q), and tetraploid/near triploid karyotype.
Conversely, high hyperdiploidy (n=29) was identified as
A. Lazaryan et al.
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Figure 1. Adjusted leukemia-free survival by cyto-
genetic risk classifications. (A) Adjusted leukemia-
free survival by modified Medical Research Council
– Eastern Cooperative Oncology Group cytogenetic
risk classification. (B) Adjusted leukemia-free sur-
vival by Center for International Blood and Marrow
Transplant Research acute lymphoblastic leukemia
risk classification. HCT: hematopoietic cell trans-
plantation.
A
B
the sole cytogenetic abnormality with a HR≤0.6 for
relapse, and was categorized as favorable risk. The
remaining cytogenetic markers, including normal cytoge-
netics, were categorized as intermediate risk (n=1566).
This novel allogeneic HCT-specific cytogenetic risk clas-
sification (hereafter called CIBMTR ALL risk) was found
to be prognostic for both post-transplant relapse (Online
Supplementary Figure S1) and leukemia-free survival (log-
rank P=0.04)  (Figure 1B). Furthermore, in the multivari-
able Cox proportional hazards model adjusted for recipi-
ent age, pre-transplant remission status, conditioning
intensity, Karnofsky Performance Status, donor type, and
GvHD prophylaxis, patients with CIBMTR adverse-risk
cytogenetics had a higher risk of treatment failure
(HR=1.26; 95% CI: 1.01-1.57, P=0.04), and those with
favorable risk had a lower risk (HR=0.6; 95% CI: 0.35-
1.02, P=0.06) compared to those with intermediate-risk
cytogenetics (Table 5). There was a significantly greater
risk of treatment failure in those with adverse versus
favorable risk cytogenetic abnormalities (HR=2.10; 95%
CI: 1.19-3.70, P=0.01). Similarly, there was a significantly
greater risk of overall mortality in patients with adverse
versus favorable risk cytogenetic abnormalities (HR=1.91;
95% CI: 1.08-3.38, P=0.03).
Discussion 
This large CIBMTR analysis of allogeneic HCT recipi-
ents with Ph– ALL defined a cytogenetic classification spe-
cific to allogeneic transplantation. Of the established
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Figure 3. Forest plots of cytogenetic markers associated with post-transplant relapse. All hazard ratios (HR) and corresponding 95% confidence intervals (CI) are
adjusted for conditiong intensity and remisssion status; CK: complex karyotype; N: sample size of carriers of each cytogenetic marker. * Defined as 40% risk increase
or decrement; **Markers with P<0.05; ΨAdjusted also for complex karyotype. DAdjusted also for monosomal karyotype.
Table 3. Multivariable model of prognostic factors for post-transplant
relapse.
Factors                               N                HR (95% CI)             P-value
Conditioning regimens
MAC (+TBI)                        1334                          1.0
MAC (-TBI)                           253                1.54 (1.22-1.96)              <0.001
RIC/NMA                                 96                 1.9 (1.38-2.61)               <0.001
Remission status pre-alloHCT
CR1                                          986                            1.0
CR2                                          733                1.71 (1.44-2.04)              <0.001
Cytogenetics
Complex karyotype*            51                 1.69 (1.06-2.69)                 0.03
Monosomy 7*                        33                 2.11 (1.04-4.27)                 0.04
N: number; HR: hazard ratio; 95% CI: 95% confidence interval; MAC: myeloablative con-
ditioning; TBI: total body irradiation; RIC: reduced-intensity conditioning; NMA: non-mye-
loablative; alloHCT: allogeneic hematopoietic cell transplantation; CR1: first complete
remission; CR2: second complete remission. *Adjusted for monosomal karyotype.
Figure 2. Cytogenetic risks by modified Medical Research Council – Eastern Cooperative Oncology Group cytogenetic risk classification and post-transplant out-
comes. All multivariable models were adjusted for recipient age, disease status, conditioning intensy, Karnofsky Performance Status, donor type and graft-versus-
host disease prophylaxis. mMRC-ECOG:  modified Medical Research Council-Eastern Cooperative Oncology Group classification with its three cytogenetic risk
groups on Y-axis, relative to the Intermediate risk (reference with HR=1) on X-axis; LFS: leukemia-free survival; OS: overall survival.
major ALL cytogenetic risk schemes, only the modified
MRC-ECOG classification could be validated in our
dataset for its association with post-transplant outcomes.
The association of the modified MRC-ECOG classifica-
tion was largely explained by favorable outcomes for
patients with high hyperdiploidy, a factor known to be
associated with better outcomes.12,13 While a few individ-
ual high-risk cytogenetic abnormalities maintained their
prognostic relevance for recipients of allogeneic HCT,
many others had no significant prognostic influence on
the transplant outcomes. Thus, the aggregate effects of
previously established high or very high risk cytogenetic
groups defined by MRC-ECOG, SWOG, NILG-ALL,
North UK, and GIMEMA 0496 were overcome by allo-
geneic HCT and did not predict the outcomes of the trans-
plant recipients. High-risk cytogenetic abnormalities
including trisomy 8, low hypodiploidy, t(1;19), del(6q)
could be overcome, in part, by the graft-versus-leukemia
effect of allogeneic HCT, and thus, were not unfavorable
in this analysis. In contrast to findings in acute myeloid
leukemia14,15 and recently reported cases of ALL,4,16 in our
dataset and elsewhere,17 monosomal karyotype did not
predict poor post-transplant outcomes for Ph– ALL.
Similarly, our analysis did not confirm the adverse effect
of t(4;11) on relapse or leukemia-free survival among all
carriers of this well-known cytogenetic risk, but uncov-
ered a differential effect of t(4;11) on transplant outcomes
which was modified by pre-transplant disease status.
Nevertheless, given the relatively small subset of patients
with t(4;11) in CR2, the results of our post-hoc analysis
should be interpreted with caution. Moreover, the infre-
quency of CR2 allografts in patients with t(4;11) may
reflect intrinsic difficulty for those patients to effectively
maintain maintain subsequent remissions. A recent com-
parison of allograft recipients with t(4;11) and normal
karyotype in CR1 demonstrated relatively favorable sur-
vival of patients with t(4;11) and especially those with
undetectable pretransplant minimal residual disease.18
Allogeneic HCT in CR1 for adult ALL patients with t(4;11)
remains valuable.19
High-risk cytogenetic abnormalities found in this study
included t(8;14), complex karyotype, and monosomy 7,
previously known poor-risk categories in major classifica-
tion schemes, excluding GIMEMA 0496 (Table 1).
Patients with these high-risk cytogenetic abnormalities
were predominantly young adults, most of whom
received myeloablative conditioning and still had poor
outcomes, thus confirming the high-risk nature of cytoge-
netic abnormalities.
The t(8;14) is a rare recurrent abnormality among
patients with ALL20-23 and has been associated with a poor
outcome.7 It was observed in ten allogeneic HCT recipi-
ents (median age, 21) who had a nearly 3-fold significantly
lower leukemia-free survival in our cohort. In addition to
the IGH-MYC fusion resulting from the t(8;14), other IGH
translocations involving BCL2 (when present together
A. Lazaryan et al.
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Table 5. Novel Center for International Blood and Marrow Transplant Research risk scheme for post-transplant Philadelphia-negative acute lym-
phoblastic leukemia outcomes
Cytogenetic risk groups                                            N                                                                               HR (95% CI)*                                 
                                                                                                        Treatment failure(1-LFS)                         Relapse                   Overall mortality (1-OS)
Favorable (high hyperdiploidy)                                        28                                   0.6 (0.35-1.02)                                  0.39 (0.15-1.05)                         0.64 (0.37-1.08)
Intermediate (normal karyotype                                   1578                               1.0 (Reference)                               1.0 (Reference)                       1.0 (Reference)
and all other abnormalities§)
Adverse (monosomy 7, complex karyotype,                125                                 1.26 (1.01-1.57)                                  1.48 (1.09-2.0)                          1.22 (0.97-1.53)
del(7q), t(8;14), t(11;19), del(11q), 
tetraploidy/near triploidy)
Adverse vs. favorable                                                            -                                     2.1 (1.19-3.7)                                   3.78 (1.36-1.76)                         1.91 (1.08-3.38)
HR: hazard ratio; 95% CI: 95% confidence interval; LFS: leukemia-free survival; OS: overall survival. *Adjusted for conditioning intensity, disease status prior to transplantation,
recipient age, Karnofsky Performance Status, donor type, graft-versus-host disease prophylaxis, as applicable based on the individual models. §Except for those included in the
adverse and favorable groups
Table 4. Multivariable model of prognostic factors for post-transplant
treatment failure.
Factors                                  N             HR (95% CI)             P-value
Age, years                                      
16-39                                          1270                       1.0
40-55                                          363            1.21 (1.04-1.41)                 0.02
55+                                              86             1.42 (1.07-1.88)                 0.01
Remission status pre-alloHCT
CR1                                            986                        1.0
CR2                                            733            1.53 (1.34-1.74)              <0.001
Conditioning regimens
MAC (+TBI)                            1334                       1.0
MAC (-TBI)                              253             1.4 (1.18-1.66)               <0.001
MAC (+TBI)                            1334                       1.0                                
RIC/NMA                                    96             1.26 (0.97-1.64)                 0.09
Performance status
KPS≥90                                    1234                       1.0
KPS<90                                    423            1.32 (1.15-1.52)              <0.001
Donor type
MSD                                          818                        1.0                                
Matched URD                         464             1.06 (0.9-1.24)                  0.49
Mismatched URD                   351            1.43 (1.21-1.68)              <0.001
Other RD/URD                         86             1.36 (1.02-1.81)                 0.03
GvHD prophylaxis
Tac-based                                  569                        1.0
CsA-based                                 996            1.11 (0.96-1.28)                 0.15
Other                                         134             1.39 (1.1-1.75)                 0.006
Cytogenetics
t(8;14)                                        10             2.85 (1.35-6.02)                0.006
Monosomy 7*                           33              1.97 (1.2-3.24)                 0.007
N: number; HR: hazard ratio; 95% CI: 95% confidence interval;  alloHCT: allogeneic
hematopoietic cell transplantation; CR1: first complete remission; CR2: second com-
plete remission; MAC: myeloablative conditioning; TBI: total body irradiation; RIC:
reduced-intensity conditioning; NMA: non-myeloablative; KPS: Karnofsky Performance
Status; MSD: matched sibling donor; RD: related donor; URD: unrelated donor;  GvHD:
graft-versus-host disease; CSA: cyclosporine. *Adjusted for monosomal karyotype.
with IGH-MYC) and CRLF2 have also been reported to
yield poor outcomes.24-26
Our study confirmed the previously established unfa-
vorable risk associated with a complex karyotype6,27 after
allogeneic HCT. Notably, we observed substantial overlap
between complex karyotype, monosomal karyotype, and
other common abnormalities, mandating careful data
analysis and interpretation of complex cytogenetics in
future studies.
Monosomy 7 was consistently associated with worse
post-transplant outcomes in this and prior studies.8
Multiple mechanisms have been proposed to explain the
effects of monosomy 7 on leukemogenesis including, but
not limited to, loss of tumor suppressor genes, haploinsuf-
ficiency, or monoallelic loss of IKZF1, an important
adverse prognostic marker in B-cell ALL which is localized
to chromosome 7p.28,29 Haploinsufficient deletions of
IKZF1 are enriched among Ph– ALL cases and associated
with inferior survival.30
Our observed higher risk of relapse among allogeneic
HCT recipients with t(11;19) was also consistent with the
previously reported poor survival of ALL patients with
t(11;19)(q23;p13.3).31
We propose an allogeneic HCT-specific cytogenetic risk
classification for Ph– ALL separating patients into three
prognostic risk categories based on the presence of mono-
somy 7, del(7q), t(8;14), t(11;19), del(11q), complex,
tetraploid/near triploid, and high hyperdiploid karyotypes
(Table 5). This novel CIBMTR ALL risk classification of
Ph– patients treated with allogeneic HCT is directly rele-
vant to pre-HCT decision-making and might help in strat-
ifying clinical trial candidates undergoing allogeneic HCT
for Ph– ALL. 
Unfortunately we could not account in our analysis for
pre-transplant minimal residual disease (MRD), defined
by flow cytometry or FISH/molecular testing. Pre-trans-
plant MRD has been important in predicting ALL relapse
and future research should combine cytogenetic classifica-
tions with pre-transplant MRD status. Pretreatment com-
plex karyotype and low hypodiploidy/near-triploidy por-
tended poor survival after adjustment for MRD in a recent
single-institution study.27 Our analysis validated other
established patient- and transplant-related prognostic fac-
tors and thereby confirmed the additional importance of
the cytogenetic groupings. As most patients in this cohort
received allografts with myeloablative conditioning,
future validation of the CIBMTR ALL risk scheme among
recipients treated with reduced intensity conditioning will
test this prognostic tool in older and/or less fit ALL
patients. 
Our study focused on the transplant period preceding
Food and Drug Administration approvals and broader use
of liposomal vincristine, blinatumomab, inotuzumab
ozogamycin, or tisagenlecleucel, and it thereby focused on
a more homogeneous patient population with no differen-
tial effect on treatment outcomes found according to quin-
quennial transplant periods from 1995 to 2011. 
While many patients with previously established high-
risk Ph– cytogenetic abnormalities can benefit from allo-
geneic HCT, those with monosomy 7, complex kary-
otype, and t(8;14) remain at high risk for treatment failure
after transplantation. Selective targeting of these and other
clinically-defined high-risk cohorts will be necessary to
improve post-transplant survival of patients with Ph– ALL. 
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